Skip to content

Bioequvalence research of Nematavir Tablets/Ritonavir Ttablets (co-packaged) in healthy people (under fasting condition)

Bioequvalence research of Nematavir Tablets/Ritonavir Ttablets (co-packaged) in healthy people (under fasting condition)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068546
Enrollment
Unknown
Registered
2023-02-23
Start date
2023-02-17
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy people

Interventions

group ?:The first period of oral test preparation on an empty stomach, the elution period is 5 days, the second period of oral reference preparation on an empty stomach, the elution period is 5 days,
group ?:The first period of oral reference preparation on an empty stomach, with an elution period of 5 days, the second period of oral test preparation on an empty stomach, with an elution period of
group ?:The first period of oral reference preparation on an empty stomach, with an elution period of 5 days, the second period of oral reference preparation on an empty stomach, with an elution perio

Sponsors

Yue Bei People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)Healthy male or female Chinese adults, aged 18 or older (2)Body mass indexes (BMIs) ranging from 19 to 26 kg/m2, and weights higher than 50kg (3)Willing to participate the trial and signed informed consent forms

Exclusion criteria

Exclusion criteria: (1)smoke more than five cigarettes per day (2)had history or condition of severe hepatic, cardiovascular, gastrointestinal, renal disease or any disease that could interferes with the results of the test (3)had condition of biliary obstructive disorders (4)A history of allergy to drugs, foods, or other substances or hypertensive to Mycophenolate Sodium, Mycophenolic acid, Mycophenolate mofetil or any excipient included (5)drug abuse within 12 months prior to screening (6)had received any other medication within fourteen days prior to the start of study (7)participated in any clinical study within 3 months prior to the screening (8)donation or loss more than 400 mL of blood within 3 months prior to the screening (9)take other medicines or food supplementary or vitamins within 14 days before first study drug administration (10) alcohol breath test or drug abuse screening positive (11) used any strong CYP3A4 inhibitor, strong CYP3A4 inducer, or drug that interacted with the study drug within 30 days before taking the study drug for the first time and who were judged by the investigators to be unfit to participate in the trial.

Design outcomes

Primary

MeasureTime frame
Cmax;AUC0-t;AUC0-8;

Secondary

MeasureTime frame
adverse event;Serious adverse events;

Countries

China

Contacts

Public ContactWenmao Fan

Yue Bei People's Hospital

418681770@163.com07516913882

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026